Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary reportChristopher W. Seymour, Yaseen M. Arabi, Djillali Annane et al.|medRxiv|2021Cited by 137
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trialLennie Derde, Ville Pettilä, Anthony Gordon et al.|Thorax|2025Cited by 12
NUDT22 promotes cancer growth through pyrimidine salvage and the TCA cycleMelanie Walter, Patrick Herr, Florian Mayr et al.|Research Square|2022Cited by 0